In phase II studies of MEK162 in patients with N-Ras and B-Raf mutated advanced melanoma, more than 50% disease control was observed with acceptable side effects, typically rash, diarrhea, fluid retention and creatinine phosphokinase elevation [6]. This evidence concerns the gene BRAF and melanoma.